Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT07197307 is registered in ClinicalTrials.gov with Universität Münster as lead sponsor.

NCT NCT07197307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07197307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Lead sponsor
Universität Münster
Phase
Phase 2
Overall status
Recruiting
Start date
October 31, 2025
Completion date
April 30, 2030
Enrollment
120 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive diffuse large b-cell lymphoma, follicular lymphoma (fl) grade 3b, high-grade b-cell lymphoma (hgbl)